医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Genetron Health to Participate at Credit Suisse Asian Investment Conference on Mar. 26th, 2021

2021年03月18日 AM05:30
このエントリーをはてなブックマークに追加


 

BEIJING

Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that management will host virtual investor meetings at the 24th Credit Suisse Asian Investment Conference on Mar. 26th, 2021.

Sizhen Wang, co-founder and Chief Executive Officer, will also attend a fireside chat at 3:00 pm Beijing time (3:00 am ET).

Interested parties may request more information by contacting their sales representative at Credit Suisse.

About Genetron Holdings Limited

Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq:GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive oncology portfolio that covers the entire spectrum of cancer management, addressing needs and challenges from early screening, diagnosis and treatment recommendations, as well as continuous disease monitoring and care. Genetron Health also partners with global biopharmaceutical companies and offers customized services and products. For more information, please visit ir.genetronhealth.com.

Safe Harbor Statement

This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as “may”, “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210317005790/en/

CONTACT

Investor Relations

US:

Hoki Luk

Head of Investor Relations

Email: hluk@genetronhealth.us

Phone: +1 (408) 891-9255

David Deuchler, CFA

Managing Director | Gilmartin Group

Email: David@gilmartinir.com

Phone: (917) 209-5605

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 参天制药和国际防盲协会合作,以实际行动执行联合国大会首个确认眼部健康与可持续发展之间存在联系的决议
  • iXensor Levels Up PixoTest® COVID-19 Ag Test With the Launch of PixoHealth Data Management Platform as the Security Solution for the New Normalcy
  • インビボスクライブがEUにおける重要な申請と中国におけるプレゼンスおよび活動の拡大を発表
  • ERS Genomicsと日本エスエルシーがCRISPR/Cas9ライセンス契約に署名
  • Mirum Pharmaceuticals and GC Pharma Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Liver Diseases in South Korea